These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7168944)

  • 21. Levodopa therapy in Parkinson's disease.
    Koller WC; Hubble JP
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 40-7; discussion 47-9. PubMed ID: 2215973
    [No Abstract]   [Full Text] [Related]  

  • 22. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
    Marsden CD
    Mod Trends Neurol; 1975; 6():141-66. PubMed ID: 127927
    [No Abstract]   [Full Text] [Related]  

  • 23. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 24. [Parkinson disease, adverse effects of chronic levodopa therapy and drug holidays].
    Bermejo F; Martínez P; de Yébenes JG
    Arch Neurobiol (Madr); 1986; 49(5):300-2. PubMed ID: 3789894
    [No Abstract]   [Full Text] [Related]  

  • 25. Problems in the contemporary treatment of parkinsonism.
    Eadie MJ
    Med J Aust; 1985 Jan; 142(2):113-7. PubMed ID: 2981393
    [No Abstract]   [Full Text] [Related]  

  • 26. Parkinson's disease: fewer treatment withdrawals with levodopa.
    Prescrire Int; 2015 Dec; 24(166):302. PubMed ID: 26788582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
    Li XM; Juorio AV; Paterson IA; Boulton AA
    J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
    [No Abstract]   [Full Text] [Related]  

  • 28. The treatment of early Parkinson's disease: levodopa rehabilitated.
    Vlaar A; Hovestadt A; van Laar T; Bloem BR
    Pract Neurol; 2011 Jun; 11(3):145-52. PubMed ID: 21551108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine dysregulation syndrome in Parkinson's disease patients on duodenal levodopa infusion.
    Cannas A; Solla P; Marrosu MG; Marrosu F
    Mov Disord; 2013 Jun; 28(6):840-1. PubMed ID: 23801562
    [No Abstract]   [Full Text] [Related]  

  • 32. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 33. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
    Calabresi P; Di Filippo M; Ghiglieri V; Tambasco N; Picconi B
    Lancet Neurol; 2010 Nov; 9(11):1106-17. PubMed ID: 20880751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the treatment of Parkinson's disease.
    Wirz D
    Conn Med; 1985 Oct; 49(10):633-7. PubMed ID: 3933903
    [No Abstract]   [Full Text] [Related]  

  • 35. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [L-threo-DOPS therapy and parkinsonism].
    Narabayashi H
    No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
    [No Abstract]   [Full Text] [Related]  

  • 37. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
    Rylander D; Parent M; O'Sullivan SS; Dovero S; Lees AJ; Bezard E; Descarries L; Cenci MA
    Ann Neurol; 2010 Nov; 68(5):619-28. PubMed ID: 20882603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract]   [Full Text] [Related]  

  • 39. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS; Snider SR; Fahn S
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.